What is claimed is:

1. A lens care solution comprising:

0.01 to about *5* weight percent of imidazole;

an effective amount of biologically compatible buffer system to maintain the pH of the solution between *6.5* and 7.8 pH, and

the balance water.

Sub A1

2. A lens care solution comprising:

0.0 ito about *5* weight percent of imidazole; an effective amount of tonicity agent ; and

the balance water

3 .A lens care solution comprising:

0.0 ito about 5 weight percent of imidazole; an effective amount of a preservative agent;

and the balance water

3. A method for treating a contact lens in order to decrease its affinity to protein

deposition which comprises the step of:
Soaking a contact lens in an aqueous solution comprising 0.01 to 5 weight percent imidazole.

4. The solution of claim 1 which further comprises 0.01 to 2 weight percent of a physiologically acceptable tonicity agent adjusted so the solution is isotonic between 200 and 400 mOsm

5. The solution of claim 4 that further comprises 0.00001 to 0.1 weight percent of a preservative.

6. The solution of claim 1 wherein the buffer is selected from the group consisting of organic amines, organic carboxylic acids, amphoterics, phosphates, or borates.

7. The method of claim 3 wherein the aqueous solution further comprises the buffer bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis–Tris) and its salts.

8. The method of claim 3 wherein the aqueous solution further comprises the 1,2-bis[tris(hydroxymethyl)-methylamino}propane (Bis-Tris Propane) and its salts.

9. The method of claim 3 wherein the aqueous solution further comprises the N-tris(hydroxymethyl) methyl glycine (Tricine) and its salts.

10. The method of claim 3 wherein the aqueous solution further comprises the N,N-bis(2-hydroxyethyl)-glycine (Bicine) and its salts.

11. The method of claim 3 wherein the aqueous solution further comprises the betaine and its salts.

12. The method of claim 3 wherein the aqueous solution further comprises the buffer phosphate and its salts

13. The method of claim 3 wherein the aqueous solution further comprises the buffer is borate and its salts

14. The method of claim 3 wherein the aqueous solution further comprises the is citrate and its salts

15. The method of claim 3 wherein the aqueous solution further comprises is TRIS and its

salts

16. The method of claim 3 wherein the aqueous solution further comprises the buffer is 2-amino-2-methyl-1,3-propanediol and its salts

17. The method of claim 3 wherein the aqueous solution further comprises the buffer is triisopropanolamine and its salts

18. The method of claim 3 wherein the aqueous solution further comprises the buffer is carnitine and its salts

19. The method of claim 3 wherein the aqueous solution further comprises the buffer is dimethyl glutamate and its salts

20. The method of claim 3 wherein the aqueous solution further comprises the buffer is creatine and its salts

21. The method of claim 3 wherein the aqueous solution further comprises the buffer is diethanolamine and its salts

22. The method of claim 3 wherein the aqueous solution further comprises the buffer is diisopropylamine and its salts

23. The method of claim 3 wherein the aqueous solution further comprises the buffer is triethanolamine and its salts

24. The method of claim 3 wherein the aqueous solution further comprises the buffer is triethylamine and its salts

25. The method of claim 3 wherein the aqueous solution further comprises the buffer is dimethyl aspartic acid and its salts

26. The method of claim 3 wherein the aqueous solution further comprises the buffer is imidazole and its salts

27. The method of claim 3 wherein the aqueous solution further comprises the buffer is histidine and its salts

28. The method of claim 3 wherein the aqueous solution further comprises the buffer is methyl aspartate and its salts.